Tirzepatide

Dual-action weight loss for faster, sustained results. Description: Tirzepatide is an FDA-approved dual GLP-1/GIP receptor agonist that targets two hunger-regulating pathways simultaneously. Clinical trials showed up to 20% body weight reduction — making it the most effective weight loss medication currently available. Once-weekly injection. Key Benefits: Targets two metabolic pathways (GLP-1 + GIP) for greater efficacy Reduces appetite and cravings significantly Improves insulin sensitivity and metabolic markers One injection per week Form: Subcutaneous injection Supply: 60mg vial ~ 12-24 weeks depending on dose